Janssen obtains FDA OK for Carvykti
Carvykti provides a treatment for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.